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Abstract
Background: 17a-Ethynyl-5-androsten-3b,7 b,1 7 b-triol (HE3286) is a synthetic derivative of an endogenous steroid
androstenetriol (b-AET), a metabolite of the abundant adrenal steroid deyhdroepiandrosterone (DHEA), with broad
anti-inflammatory activities. We tested the ability of this novel synthetic steroid with improved pharmacological
properties to limit non-productive lung inflammation in rodents and attempted to gauge its immunological
impact.
Methods and Results: In mice, oral treatment with HE3286 (40 mg/kg) significantly (p < 0.05) decreased
neutrophil counts and exudate volumes (~50%) in carrageenan-induced pleurisy, and myeloperoxidase in
lipopolysaccharide-induced lung injury. HE3286 (40 mg/kg) was not found to be profoundly immune suppressive
in any of the classical animal models of immune function, including those used to evaluate antigen specific
immune responses in vivo (ovalbumin immunization). When mice treated for two weeks with HE3286 were
challenged with K. pneumoniae, nearly identical survival kinetics were observed in vehicle-treated, HE3286-treated
and untreated groups.
Conclusions: HE3286 represents a novel, first-in-class anti-inflammatory agent that may translate certain benefits of
b-AET observed in rodents into treatments for chronic inflammatory pulmonary disease.
Introduction
Chronic obstructive pulmonary disease (COPD), a term
most often used to describe chronic bronchitis and
emphysema [1,2] is an inflammatory disease of the lungs
marked by a loss of elastic recoil, an increased resistance
to airflow and decreased expiratory flow rate leading to
dyspnea [3]. Chronic bronchitis, emphysema and cystic
fibrosis (CF), all forms of COPD, share many features
including a progressive airway remodeling driven by
chronic inflammation [4-7]. COPD is a major cause of
morbidity and mortality in industrialized countries and
novel treatments are urgently needed because many
patients respond poorly to conventional therapies [8-10].
Even in responders, narrow therapeutic windows and a
myriad of unwanted side effects, including immune sup-
pression are treatment limiting [9-12]. We have suggested
that suitable agents may be found within the adrenal
metabolome [13].
Dehydroepiandrosterone (DHEA) is an abundant adre-
nal steroid and a precursor in the biosynthesis of andro-
gens, estrogens and other anti-inflammatory immune
regulating steroids [14,15]. From studies reporting aber-
rant metabolism of adrenal steroids in CF patients
[16,17] we surmised that novel anti-inflammatory thera-
peutics relevant to lung inflammation might be found
within the DHEA metabolome. A large body of literature
reports that DHEA replacement therapy (in animals,
especially rodents) provides striking therapeutic benefits
a c r o s saw i d er a n g eo fd i s e a s em o d e l s[ 1 8 ] .H o w e v e r ,
DHEA replacement therapy in humans repeatedly failed
to provide the same benefits observed in rodents [19-21].
Failures are attributed to poor (~3%) oral bioavailability,
and a differential metabolism between rodents and
humans that leads to different dominant downstream
metabolic species [22-25]. Rodents rapidly metabolize
exogenous DHEA into a surprisingly complex array of
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that these metabolites may be responsible for activities
attributed to DHEA [13].
Androstene-3b,7 b,1 7 b-triol (b-AET) is biosynthesized
from DHEA, biologically active in rodents [29-32] and
naturally occurring in humans [33-37]. It’s functions in
the body may include tissue-specific modulation of gluco-
corticoid (GC) action, immune function, and control of
acute and chronic inflammation [38-40]. Despite these
promising properties, b-AET suffers from some of the
same pharmaceutical liabilities as DHEA, including meta-
bolic instability and low oral bioavailability. Extensive
screening studies demonstrated that HE3286, a synthetic
derivative of b-AET, possessed surprising pharmaceutical
properties including good oral bioavailability in rodents,
primates and humans and significant resistance to steroi-
dogenic metabolism, as evidenced by studies using human
microsomes (Harbor Biosciences, unpublished observa-
tions). HE3286 also possessed anti-inflammatory proper-
ties, providing benefit in several animal models of
immune-mediated inflammatory diseases [41-43]. In this
report, we explore the potential of HE3286 for the treat-
ment of lung inflammation using the murine models of
carrageenan-induced pleurisy and LPS-induced lung
injury. Immunological safety was assessed in the CFTR
-/-
mouse model of CF, ovalbumin immunization, and in sur-
vival kinetics of mice challenged with lethal doses of the
common lung pathogen, Klebsiella pneumoniae. The pre-
sent studies, in context of our previous reports, suggest
that HE3286 might also provide safe and effective treat-
ment for patients with inflammatory diseases of the lung.
Materials and methods
Drugs
The test compounds HE3286 (17a-ethynyl-5-androstene-
3b,7 b,1 7 b-triol), HE2000 (16a-bromoepiandrosterone)
and vehicles (HERF405 or HERF202) were prepared and
provided by Harbor Biosciences (San Diego, CA).
HERF202 contains 30% b-cyclodextrin sulfobutyl ether
sodium salt (w/v) in water. HERF405 contains 0.1% car-
boxymethylcellulose, + 0.9% NaCl + 2% Polysorbate 80 +
0.05% phenol. HE3286 was dissolved in HERF202 or sus-
pended in HERF405 and administered by oral gavage and
by subcutaneous injection (SC), respectively.
Animal Care
Animals were purchased and housed in accordance with
respective institutional guidelines and requirements of
the relevant regulatory agencies. All studies were
approved by the relevant institutional ethics committees.
Pleurisy studies were performed by F.N. at University of
Catania, Italy; LPS induced lung injury studies were per-
formed by D.C. and A.W. at Veteran Affairs San Diego
Medical Center; CFTR knockout mice studies were
performed by A.V. at Case Western University, Cleve-
land, OH. Ovalbumin immunization and popliteal lymph
node assays were performed by R.P at Utrecht University,
and bacterial challenge studies were performed at
Explora Biolabs (San Diego, CA)
Carrageenan (CAR) -induced pleurisy mouse model
Animals
Six to 8 week old CD1 male mice (Charles River, Calco,
Italy) were housed in a controlled environment and pro-
vided with standard rodent chow and water. All animals
weighed approximately 25-30 grams each. These mice
were acclimated for at least 3 days prior to the start of the
experiment.
Experimental groups
Mice (n = 10 per group) were allocated into one of the
following groups as follows: (1) Sham (saline) treated
animals; (2) CAR only (CAR group); (3) CAR and vehi-
cle (HERF405 by SC injection); (4 and 5) CAR and
HE3286 (SC injection of either 40 or 4 mg/kg in vehi-
cle); and (6) CAR and rabbit anti-mouse polyclonal
anti-TNFa antibody (200 μg in saline, IP injection). All
treatments were given 24 h and 1 h prior to CAR in a
final volume of 0.1 mL.
Pleurisy Assay
Mice were anaesthetized with isoflurane and the skin
was incised at the level of the left sixth intercostal
space. The underlying muscle was dissected and saline
(sham) or saline containing 2% l-CAR (Sigma-Chimica,
Milan, Italy) was injected into the pleural cavity. The
skin incision was closed with a suture and the animals
were allowed to recover. At 4 h after the injection of
CAR, the animals were sacrificed by CO2 asphyxiation.
The chest was carefully opened and the pleural cavity
rinsed with 1 mL of saline solution containing heparin
(5 U/mL) and indomethacin (10 μg/mL). The exudate
and washing solution were removed by aspiration and
the total volume measured. Any exudate, which was
contaminated with blood, was discarded. The amount of
exudate was calculated by subtracting the volume
injected (1 mL) from the total volume recovered. The
leukocytes in the exudate were suspended in phosphate-
buffer saline (PBS) and counted with an optical micro-
scope in a Burker’s chamber after vital Trypan Blue
staining. No differential cell counts were conducted, as
cells at this time point are predominantly neutrophils
[44]. Data are expressed as mL exudate volume or mil-
lions of neutrophils per mouse +/- standard deviation
LPS -induced lung injury model
Animals
Six to 8-week old C57 black/6 male mice (approximately
25-30 grams, Harlan, San Diego, CA) were used in these
studies (at least 4-8 animals per group). These mice
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the experiment. The animals were housed in a con-
trolled environment and provided with standard rodent
chow and water.
Chemicals and Reagents
LPS was prepared from Escherichia coli 055:B5 (Sigma,
St. Louis, MO)pou. Myeloperoxidase (MPO) enzymatic
activity was assessed as previously described [45]. TNFa
and IL-6 EIA kits were purchased from Assay Designs
(Ann Arbor MI).
Lung injury model
Animals were treated with HE3286 or with vehicle
(HERF405) via a single gavage administration (0.1 mL)
24 h and 1 h before LPS challenge. LPS challenge was
performed by lightly anesthetizing the mice with iso-
fluorane, and then directly administering the LPS
(5 mg/kg, 50 μL; 1 mg diluted in 1 mL sterile saline)
into the trachea under direct observation with a gel
loading pipette through a medical otoscope. The mice
were placed in a vertical position and rotated for 0.5 - 1
min to distribute the instillate evenly within the lungs.
At 48 h after the LPS challenge, animals were sacrificed,
bronchoalveolar lavage (BAL) samples taken (BAL per-
formed 3× using sterile PBS; 1.3 mL were typically
recovered) cells counted using a hemacytometer and
cytokine levels were measured by ELISA.
Ovalbumin mouse immunization studies
Female BALB/c mice (5 per group) were sensitized by
intraperitoneal injection (total volume 0.2 mL) on days 1
and 8 with 100 μg ovalbumin (endotoxin-free OVA
from Sigma Aldrich, Zwijndrecht, the Netherlands) pre-
cipitated with aluminum hydroxide (Sigma Aldrich) in
saline. Mice were treated (gavage) daily with HE3286
(40 mg/kg) or with vehicle (HERF202) on days 0-20.
On day 20, 2 h after the final treatment, blood was
drawn by terminal cardiac puncture, serum prepared
a n dt e s t e db yE L I S Af o ra n t i b o d yt i t r e sa g a i n s tO V A .
Briefly, OVA was coated overnight (4°C) on 96 well
plates (high bond 3950 Costar plates, Cambridge MA)
in carbonate buffer (pH 9.6), and then blocked with
PBS-Tween 20/3% milk powder (Campina melkunie, the
Netherlands) for 1 h at 37°C. Serum diluted in PBS-
Tween 20 (0.5%) was incubated in the wells for 1 h,
followed with incubation (1 h, 37°C) with alkaline phos-
phatase-conjugated anti-IgG1 antibodies (Southern Bio-
technology Association Inc., Birmingham, USA).
Subsequently, 1 mg/mL p-nitrophenylphosphate in
diethanolamine buffer was used for the color reaction,
which was stopped with an EDTA solution. Absorbance
at 450 nm was measured using an ELISA reader
(ELX800, Biotek Instruments-Inc, Winooski).
Klebsiella pneumoniae survival study
Animals
Female BALB/c mice (approximately 25-30 grams,
Harlan, San Diego, CA) were used in these studies.
Mice were acclimated for at least 3 days prior to the
start of the experiment.
Challenge
Animals were randomized by weight into 4 groups.
Group 1 (n = 10) received daily 0.1 mL administrations
(gavage) of HE3286 at 80 mg/kg in vehicle (HERF405).
Group 2 (n = 10) received equal volumes of vehicle
alone. Group 3 (n = 10) received daily IP administrations
of dexamethasone (dex; 0.4 mg/kg, Sigma, St. Louis, MO)
in 0.1 mL saline. Group 4 (n = 8) was untreated. Body
weights were measured daily. After 14 days of treatment,
infection was induced by subcutaneous inoculation of
10
7 colony-forming units (LD50 at 72 hours; Harbor Bios-
ciences, unpublished observations) of K. pneumoniae
(strain AFRRI7). Once daily treatments were given until
death. All animals were monitored twice-daily for health
status until the end of the study.
Studies in CFTR knockout mouse model
Animals
STOCK Cftr
tm1Unc-TgN(FABPCFTR)#Jaw were bred,
housed and used as in our previous studies [46,47].
Male mice (9 per group) 6-8 weeks of age, body weight
at least 16 g, were used in these experiments and bred
and housed under standard laboratory conditions.
Infection model
The slow growing mucoid clinical strain P. aeruginosa
M57-15 was used in these studies. P. aeruginosa-laden
agarose beads were made and used, as described pre-
viously [46,48] with minor differences. Mice were inocu-
lated with a 1:35 dilution of the beads. (LD50 dose).
HE3286, HE2000 (0.1 mL) or vehicle (HERF202) was
given by oral gavage 24 h before and 1 h after bacterial
challenge. Measurements of bacterial burden in the
lungs were performed as in our previous studies [49].
Statistical Analysis
For pleurisy studies, all parameters of interest were sub-
jected to ANOVA with Duncan’s new multiple-range
post hoc testing between groups. For lung injury studies,
data were analyzed by two-sided Student’s t test. For
C F T Rk n o c k o u tm o u s es t u d i e s ,d a t aw e r ea n a l y z e db y
one-way ANOVA and stratified Mann-Whitney. For
OVA immunization studies, analysis was performed
using the SAS® system, (version 9.1) with certain exact
tests implemented by use of the StatXact® (version 7)
software package [50]. For Klebsiella pneumoniae survi-
val studies, comparison of survival curves (Logrank test
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Diego, CA).
Results
HE3286 and HE2000 appeared well tolerated throughout
the course of these studies. No drug related frank toxi-
city (i.e., animals found dead or in moribund condition)
or unexpected weight loss was observed in any of the
treated animals as compared to vehicle controls (data
not shown).
Effect of HE3286 in carrageenan-induced pleurisy mouse
model
When mice were challenged with 0.l mL of 2% carragee-
nan in the pleural cavity, high leukocyte numbers (~1.9 ×
10
6 per mouse) were observed in the pleural exudate.
Substantially lower leukocytes numbers (~2.8 × 10
5 per
mouse) were observed in animals undergoing a sham
procedure and challenged with saline (Figure 1). When
mice were pre-treated with HE3286 (40 mg/kg) by sub-
cutaneous injection, significantly (p < 0.05) reduced num-
bers of carrageenan-induced neutrophils (~5.7 × 10
5)
were observed in pleural exudates compared to those
observed in animals given vehicle alone (~1.8 × 10
6).
The 4.0 mg/kg dose was not effective. Treatment with
high-dose HE3286 was as effective as treatment with
polyclonal anti-mouse TNFa antibody, positive control.
Treatment with HE3286 also reduced pleural exudate
volumes (compared to vehicle), in a dose-dependent
fashion.
Effect of HE3286 in the LPS-induced lung injury mouse
model
The ability of HE3286 to reduce lung inflammation was
also tested in the LPS-induced acute lung injury model.
A meta-analysis of two independent studies revealed that
when mice pre-treated with HE3286 (40 mg/kg) by oral
gavage were challenged with 50 mg of LPS, levels of
MPO in lungs at 48 hours were significantly (p < 0.025)
reduced (~30%) compared to vehicle-treated animals
(Figure 2). Reductions in MPO were also observed with
HE3286 at lower doses (12 and 1.2 mg/kg), but as with
inflammatory cells and cytokines (TNFa and IL-6) in
bronchoalveolar lavage fluid (BAL), upon meta-analysis,
these changes did not achieve statistical significance (data
not shown).
Effect of HE3286 in the murine ovalbumin
immunization model
We have shown in previous studies that HE3286 does
not suppress either delayed type hypersensitivity
responses [51] or mixed lymphocyte responses [42],
classical measures of cell mediated (i.e., Th1) biased
immunity. HE3286 showed no suppressive activity or
Figure 1 Effect of HE3286 treatment on carrageenan-induced pleurisy. Mice CD1 mice (10 per group) were anesthetized and saline (0.1
mL) alone (sham) or saline containing 2% carrageenan (CAR) was injected into the pleural cavity. Mice were treated (sc) with HE3286 (4 or 40
mg/kg) or vehicle HERF405 alone (0.1 mL) 24 h before and 1 h before CAR. At 4 h after CAR, the animals were killed, the chest opened, and the
pleural cavity rinsed with 1 mL of saline solution. The leukocytes in the exudate were suspended in phosphate-buffer saline (PBS) and counted.
Data are expressed as mL exudate volume (A) or millions of neutrophils (B) per mouse +/- standard deviation on the Y-axis. Treatment groups
are identified on the X-axis. *p < 0.05.
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node assay [51]. Immunization with ovalbumin in alum
adjuvant is a classical approach to induce antibody (i.e.,
Th2) biased immune responses [52]. Profound immune
suppression was not observed in the murine ovalbumin
immunization model. However, a small (~25%) but sta-
tistically significant (p < 0.05) reduction in OVA specific
antibody production was observed in mice treated with
HE3286 (Figure 3). The statistical analysis shows that, in
terms of derived IgG1 absorbance, HE3286 is inferior to
its vehicle (p = 0.008). The exact confidence interval for
the difference in median absorbance is negative, indicat-
ing that the distribution of HE3286 optical density is
unlikely to be on a par with that of its vehicle.
In order to estimate the clinical relevance of the above
finding and to assess the immunological impact of treat-
ment with HE3286, studies in mice challenged with
opportunistic lung pathogens were undertaken.
Effect of HE3286 on opportunistic bacterial infections of
the lung
A major limitation of GC treatment, and a potential
advantage of HE3286, is that the former is immune sup-
pressive and the latter is not. The following studies were
designed to demonstrate this, especially in the context
of opportunistic infections.
1. K. pneumoniae
K. pneumoniae is an opportunistic infection commonly
observed in immune suppressed mice [53]. When ani-
mals were challenged with 10
7 cfu of K. pneumoniae,n o
significant differences in survival kinetics were found
between HE3286-treated, vehicle-treated or untreated
groups. Fifty to 60% of animals in these groups survived
to day 3 (Figure 4). In contrast, in the dex-treated
group, only 20% of animals were alive on day 3. This
difference (p =0 . 0 7vs untreated) suggested that dex-
treated animals succumbed to infection more quickly
than controls. Mice treated with HE3286 appeared to
gain more weight compared to other groups. At the
time of bacterial challenge, there was a significant (p =
0.01) difference between control, dex-treated and
HE3286-treated animals. After bacterial challenge, con-
trols and dex-treated animals appeared to lose weight
faster and to a greater extent than the HE3286-treated
mice (data not shown).
2. HE2000, but not HE3286, reduced bacterial burden in the
CFTR mouse model
P. aeruginosa is another opportunistic bacterial patho-
gen that is commonly found resident in lungs of
patients with CF [54]. In the context of the present stu-
dies, it was deemed important to demonstrate that
HE3286 did not exacerbate bacterial burden in this
COPD-like setting. In this study, another synthetic ster-
oid, HE2000, was used as a positive control, to demon-
strate that the bacterial burden delivered to these
animals was indeed amenable to pharmacological
manipulation. Neither HE3286 nor HE2000 (positive
control) treatment induced frank toxicity in the CFTR
-/
-
mouse and there was no significant (ANOVA) difference
between groups (vehicle versus drug-treated) with
respect to body weight or bronchoalveolar lavage cell
counts at 24 hours after bacterial challenge (data not
shown). There was significantly greater numbers of bac-
teria in vehicle-treated mice compared to 40 mg/kg
HE2000 (p < 0.03) as was found in our previous studies
[55]. In contrast, we found no significance with respect
to a reduction of bacteria in HE3286- compared to vehi-
cle-treated mice (Table 1).
Discussion
We have shown that in rodent models of lung-associated
inflammation, HE3286 acts as an anti-inflammatory
steroid without clinically relevant immune suppression.
HE3286 treatment reduced inflammation in carragee-
nan-induced pleurisy as judged by reduced numbers of
neutrophils and pleural exudate volumes and in the
LPS-induced lung injury model as judged by reduced
MPO in BAL fluid. HE3286 treatment was safe in the
CFTR mouse model (no observed increase in bacterial
burden) and induced only slight suppression of antigen
specific antibody production in the OVA immunization
model. The limited adverse immunological impact of
this latter observation was clearly demonstrated in ani-
mals treated (for 14 days) with HE3286 and then chal-
lenged with a lethal bacterial infection. These animals
Figure 2 Effect of HE3286 treatment on MPO levels in LPS
induced Lung Injury. On day-1, male C57 black/6 mice were pre-
treated (gavage) with HE3286 or 0.1 mL vehicle (HERF405). The next
day, mice were challenged with 50 μg of E-coli LPS under direct
visualization of trachea under light anesthesia. Sixty minutes after
the LPS challenge, mice were treated with a second dose of
HE3286, or vehicle. Forty-eight hours after LPS challenge, mice were
sacrificed and myeloperoxidase (MPO) activity in lungs determined
as previously described [45]. Results are from two identical
experiments. Data are expressed as O.D at 460 nM.
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intraperitoneal injection (total volume 200 μL) on days 1 and 8 with 100 μg OVA precipitated with alum (25 mg/mL) in saline. Animals were
treated (gavage) with HE3286 (40 mg/kg) or with HERF202 vehicle (100 μL) alone once daily for twenty days. On day twenty, animals were
sacrificed and OVA-specific immunolglobulin (IgG) levels in serum were measured at various dilutions by ELISA. Data are expressed as optical
density +/- standard deviation on the Y-axis versus dilution on the X-axis.
Figure 4 Effect of HE3286 on bacterial infection. Female BALB/c mice (n = 8-10 per group) received daily 0.1 mL administrations (gavage) of
HE3286 at 80 mg/kg in vehicle (HERF405), equal volumes of vehicle alone, daily IP administrations of dexamethasone (dex; 0.4 mg/kg) in 0.1 mL
saline or sham treated. After 14 days of treatment, infection was induced by SC inoculation of 10
7 colony-forming units (cfu) of K. pneumoniae.
Daily HE3286 or dex treatments continued and all animals monitored twice-daily until the end of the study for health status.
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untreated mice. As expected, mice treated with the
well-known immune suppressive agent dexamethasone
succumbed to infection faster than either of the
untreated groups.
The activity of HE3286 in pleurisy suggests a pro-
found anti-inflammatory effect of HE3286 on the early
events driving acute lung inflammation. Significant
decreases in both neutrophils and exudate volumes were
observed 4 hours after carrageenan challenge. HE3286
was also tested in two independent LPS-induced lung
injury studies. The activity of HE3286 later in the acute
inflammatory response (i.e., 48 hours after challenge)
was most apparent in these studies when the compound
was given at the highest dose (40 mg/kg). Meta-analysis
of the two studies revealed significantly reduced levels
of MPO in lungs and non-significant reductions in pro-
inflammatory cells and cytokines in BAL. Lower doses
of HE3286 appeared less effective since reductions did
not reach statistical significance in our meta-analysis.
Observations in BAL were likely limited by variability in
the assay, its kinetics [56-58] and statistical limitations
imposed by the small number of animals per study.
Nevertheless, the preponderance of evidence in this
model confirms an anti-inflammatory activity of HE3286
relevant to lung inflammation.
Our observations that HE3286 possesses significant
anti-inflammatory activity in both carrageenan and LPS-
induced lung inflammation are consistent with our ear-
lier observations in models of rheumatoid arthritis
[41,42], experimental autoimmune encephalitis and coli-
tis [43]. We reported that oral HE3286 treatment signif-
icantly decreased disease scores in all models. In our
rodent model studies of rheumatoid arthritis, we found
that HE3286 treatment benefit was associated with
reduced IL-17, TNFa and IL-6 signaling and dramatic
reductions in IL-6 and matrix metalloproteinase mRNA
in inflamed joint tissue accompanied by an expansion of
regulatory T cells in the spleen [51]. Differential
HE3286 dosing effects have been observed between the
various rodent disease models. For example, in EAE,
HE3286 was effective at 4 mg/kg [43], while in RA
models, the minimally effective dose was 10 fold higher
[41]. And in the rat model of colitis, 30 mg/kg was less
effective than l0 mg/kg, suggesting that in specific
instances, the compound may be more effective at
lower doses [43].
The biological mechanism by which HE3286 mediates
these effects is unknown. In our previous studies, benefit
was associated with reduced activation of NFBi ns p l e -
nocytes from LPS-challenged mice [51]. Evidence has
accumulated implicating NFB as a mediator of lung
injury in rodents [59] and as a potential target for treat-
ing COPD [3,4]. These findings suggest HE3286 down-
regulates NFB-mediated pro-inflammatory cytokine
production in the lungs. As in rodent models of rheu-
matoid arthritis, inhibition of matrix metalloproteinases
may have also played a protective role in LPS-induced
lung injury that is also characterized by a marked
increase of MMP9 in the lung [59]. The implication of
MMP3 in the tissue destruction associated with COPD
[60] further highlights some of the immunopathogenic
similarities of this disease with the LPS-induced lung
injury model and highlights the potential relevance of
these findings to the clinical setting. Regarding a possi-
ble mechanism for action of HE3286 through the TNFa
pathway, in our previoius studies we found that HE3286
caused the inhibition of the LPS-induced macrophage
activation program in vitro primarily by inhibiting
TNFa action [61]. This activity was associated with sig-
nificantly decreased phosphorylation of IKK, NFB, P38,
and JNK. HE3286 treatment was also associated with
increased regulatory T cells. This same mechanism may
also explain the HE3286 induced reduction of IgG1 we
observed in our OVA studies.
Notably, HE3286 at the highest doses was not found
to be immune suppressive in any of the classical in vitro
(mitogen induced lymphocyte proliferation) or in vivo
models (DTH, poplitieal lymph node assay, viral endo-
carditis) of immune suppression [42,51]. In the present
studies, treatment resulted in a small but significant
suppression of OVA specific antibody production. How-
ever, HE3286 was found to be safe in the CFTR
-/- male
mouse model of cystic fibrosis. Further, K. pneumoniae
challenge to animals conditioned with HE3286 resulted
in no promotion of death. Therefore, our studies in
both CFTR
-/- and K. pneumoniae challenged mice sug-
gest no clinical relevance to this observation. We specu-
late that decreased levels of IL-6 in HE3286-treated
animals may be causal to this phenomenon.
Table 1 Effect of HE3286 on bacterial burden in lungs of
CFTR
-/- Mice
CFU (in millions of units)
Group n Med (IQR) p
Vehicle 9 7.00 (4.15, 8.60) .
HE3286
40 mg/kg
8 5.35 (3.08, 8.00) 0.8026
HE2000
40 mg/kg
9 3.60 (2.10, 4.80) 0.0290
Mice were inoculated with a 1:35 dilution of P. aeruginosa-laden agarose
beads. HE3286, HE2000 (positive control) or vehicle alone was delivered by
oral gavage (0.1 mL) to mice 24 h before and 1 h after challenge with
bacteria laden beads. Bacterial colony counts were performed on whole lung
homogenates taken 24 h after the final challenge. Data are expressed as CFU
per lung.
CFU: colony forming units; p: Stratified Mann-Whitney exact p-value (versus
vehicle); IQR: Interquartile rang; n: sample size.
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HE3286 does not interact (either via binding or transacti-
vation) with any of the known nuclear hormone recep-
tors, including the glucocorticoid or sex steroid receptors
[61]. Since no dedicated nuclear receptors have ever been
identified for 7-hydroxy steroids, potential mechanisms
of action have previously been grouped into four broad
categories, including gating (ligand inactivation), modula-
tion of ion channels, interaction with atypical receptors,
and modulation of steroidogenic enzymes [38]. Potential
HE3286 targets within each of these categories are cur-
rently under consideration.I nt i s s u e s ,H E 3 2 8 6a n d / o r
metabolites may have multiple sites of interaction as is
the case for other members of the steroid hormone series
[62]. None of our observations rule out the possibility
that metabolites of HE3286 significantly contribute to the
anti-inflammatory activities and as such they must be
considered as potentially relevant in a systems biology
paradigm [63]. As a direct consequence, the pro-inflam-
matory disease process may be interrupted at multiple
nodes through restoration of homeostatic endocrinology
in the host.
HE3286 appears to ameliorate insulin resistance [64]
and colitis [65], co-morbidities commonly associated
with CF and other COPDs [66-68]. These pre-clinical
observations have lead to clinical trials. Preliminary
observations indicate that an anti-inflammatory activity
of HE3286 has been demonstrated in obese insulin resis-
tant subjects [61]. Taken together, the new data pre-
sented here suggest an even broader application for this
agent in inflammatory conditions of the lung. HE3286
may represent a novel, first in class anti-inflammatory
and disease-modifying agent that has a safety profile that
permits chronic use without the side effects produced by
the presently prescribed anti-inflammatory agents.
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